You are here

Novo Nordisk raises 2017 forecasts despite continued US price pressure

Copenhagen

NOVO Nordisk, the world's leading maker of diabetes drugs, reported a better than expected profit on Wednesday driven by new diabetes and obesity drugs, though it said sale prices would remain under pressure in the United States.

The Danish drugmaker shocked markets in

sentifi.com

Market voices on:

Powered by GET.comGetCom